Cargando…
Correction: Aclacinomycin A Sensitizes K562 Chronic Myeloid Leukemia Cells to Imatinib through p38MAPK-Mediated Erythroid Differentiation
Autores principales: | Lee, Yueh-Lun, Chen, Chih-Wei, Liu, Fu-Hwa, Huang, Yu-Wen, Huang, Huei-Mei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5636156/ https://www.ncbi.nlm.nih.gov/pubmed/29020096 http://dx.doi.org/10.1371/journal.pone.0186528 |
Ejemplares similares
-
Aclacinomycin A Sensitizes K562 Chronic Myeloid Leukemia Cells to Imatinib through p38MAPK-Mediated Erythroid Differentiation
por: Lee, Yueh-Lun, et al.
Publicado: (2013) -
Role of the aclacinomycin A--doxorubicin association in reversal of doxorubicin resistance in K562 tumour cells.
por: Millot, J. M., et al.
Publicado: (1989) -
Proteome Changes Induced by Imatinib and Novel Imatinib Derivatives in K562 Human Chronic Myeloid Leukemia Cells
por: Arvaniti, Katerina, et al.
Publicado: (2014) -
Induction of Erythroid Differentiation by 5‐Fluorouracil in K562 Leukemia Cells
por: Yang, Ya‐Wun, et al.
Publicado: (1995) -
Cytotoxicity of Isoxazole Curcumin Analogs on Chronic Myeloid Leukemia-Derived K562 Cell Lines Sensitive and Resistant to Imatinib
por: Feriotto, Giordana, et al.
Publicado: (2023)